REGN shows evidence of a price recovery underway as illustrated by momentum indicators and volumn oscillator on the daily. This is further backed up by encouraging signals on both lower and highe timeframes.交易進行
Quarterly result dissappointed esp with Eyleas facing biosimilar competition. However the company has growth prospects elsewhere and price quickly recovered. I had considered exiting at a loss but momentum indiicator was not bearish and fortunately it paid off手動結束交易
The stock yo-yoed between profit and loss and I finally closed my positions at about net break even, fortunately prior to mixed data for their Phase 3 itepekimab
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。